Jason R. Buck

Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness

Sarah Scott, Paige E. Selvy, Jason R. Buck et al. · Nature Chemical Biology · 2009 · 273 citations · Full text

Medicine, Oncology, Pharmacology +12

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity

Jana A. Lewis, Sarah Scott, Robert R. Lavieri et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 98 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer

Chirayu Shah, Todd W. Miller, Shelby K. Wyatt et al. · Clinical Cancer Research · 2009 · 84 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Quantitative Preclinical Imaging of TSPO Expression in Glioma Using <i>N,N</i>-Diethyl-2-(2-(4-(2-¹⁸F-Fluoroethoxy)Phenyl)-5,7-Dimethylpyrazolo[1,5-<i>a</i>]Pyrimidin-3-yl)Acetamide

Dewei Tang, Matthew R. Hight, Eliot T. McKinley et al. · Journal of Nuclear Medicine · 2012 · 61 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Quantitative, Preclinical PET of Translocator Protein Expression in Glioma Using ¹⁸F-<i>N</i>-Fluoroacetyl-<i>N</i>-(2,5-Dimethoxybenzyl)-2-Phenoxyaniline

Jason R. Buck, Eliot T. McKinley, Matthew R. Hight et al. · Journal of Nuclear Medicine · 2010 · 58 citations · Full text

Medicine, Nuclear Medicine, Oncology +17